Arimidex Early Breast Cancer sNDA Approval Based On Nolvadex Comparison
Executive Summary
AstraZeneca's Arimidex supplemental approval in early breast cancer is based on preliminary analysis of a 31-month efficacy comparison against AstraZeneca's Nolvadex (tamoxifen)